Search

Your search keyword '"Filippatos, Gerasimos"' showing total 19 results
Start Over Author "Filippatos, Gerasimos" Journal american heart journal
19 results on '"Filippatos, Gerasimos"'

1. Characteristics, treatment, and outcomes of early vs. late enrollees of the STRONG-HF trial

Author

Arrigo, Mattia, Davison, Beth, Edwards, Christopher, Adamo, Marianna, Ambrosy, Andrew P., Barros, Marianela, Biegus, Jan, Celutkiene, Jelena, Čerlinskaitė-Bajorė, Kamilė, Chioncel, Ovidiu, Cohen-Solal, Alain, Damasceno, Albertino, Diaz, Rafael, Filippatos, Gerasimos, Gayat, Etienne, Kimmoun, Antoine, Lam, Carolyn S.P., Metra, Marco, Novosadova, Maria, Pagnesi, Matteo, Pang, Peter S., Ponikowski, Piotr, Saidu, Hadiza, Sliwa, Karen, Takagi, Koji, Ter Maaten, Jozine M., Tomasoni, Daniela, Voors, Adriaan A., Cotter, Gad, and Mebazaa, Alexandre

Published
2024
Full Text
View/download PDF

2. Left ventricular ejection fraction digit bias and reclassification of heart failure with mildly reduced vs reduced ejection fraction based on the 2021 definition and classification of heart failure

Author

Savarese, Gianluigi, Gatti, Paolo, Benson, Lina, Adamo, Marianna, Chioncel, Ovidiu, Crespo-Leiro, Maria G., Anker, Stefan D., Coats, Andrew J.S., Filippatos, Gerasimos, Lainscak, Mitja, McDonagh, Theresa, Mebazaa, Alexandre, Metra, Marco, Piepoli, Massimo F., Rosano, Giuseppe M.C., Ruschitzka, Frank, Seferovic, Petar, Volterrani, Maurizio, Maggioni, Aldo P., and Lund, Lars H.

Published
2024
Full Text
View/download PDF

3. LEFT VENTRICULAR EJECTION FRACTION DIGIT BIAS AND RECLASSIFICATION OF HEART FAILURE WITH MILDLY REDUCED VS. REDUCED EJECTION FRACTION BASED ON THE 2021 DEFINITION AND CLASSIFICATION OF HEART FAILURE

Author

Savarese, Gianluigi, primary, Gatti, Paolo, additional, Benson, Lina, additional, Adamo, Marianna, additional, Chioncel, Ovidiu, additional, Crespo-Leiro, Maria G., additional, Anker, Stefan D., additional, Coats, Andrew J.S., additional, Filippatos, Gerasimos, additional, Lainscak, Mitja, additional, McDonagh, Theresa, additional, Mebazaa, Alexandre, additional, Metra, Marco, additional, Piepoli, Massimo F., additional, Rosano, Giuseppe M.C., additional, Ruschitzka, Frank, additional, Seferovic, Petar, additional, Volterrani, Maurizio, additional, Maggioni, Aldo P., additional, and und, Lars, additional

Published
2023
Full Text
View/download PDF

4. Finerenone and Cardiorenal Outcomes by History of Cardiovascular Disease in Patients with Type 2 Diabetes: Fidelity Analyses

Author

Filippatos, Gerasimos, primary, Anker, Stefan D., additional, Pitt, Bertram, additional, Rossing, Peter, additional, Ruilope, Luis M., additional, McGuire, Darren K., additional, Jankowska, Ewa A., additional, Michos, Erin D., additional, Butler, Javed, additional, Farjat, Alfredo E., additional, Kolkhof, Peter, additional, Scalise, Andrea, additional, Joseph, Amer, additional, Viaud, Marco A.L., additional, Bakris, George L., additional, and Agarwal, Rajiv, additional

Published
2022
Full Text
View/download PDF

5. Finerenone in Mild to Severe Chronic Kidney Disease and Type 2 Diabetes: A Fidelity Subgroup Analysis in Patients with Heart Failure

Author

Filippatos, Gerasimos, primary, Agarwal, Rajiv, additional, Anker, Stefan D., additional, Rossing, Peter, additional, Joseph, Amer, additional, Kolkhof, Peter, additional, Lambelet, Marc, additional, Viaud, Marco A.L., additional, Ruilope, Luis M., additional, Bakris, George L., additional, and Pitt, Bertram, additional

Published
2022
Full Text
View/download PDF

7. Importance of trial design when investigating cardiorenal outcomes in patients with CKD and T2D: Focus on CREDENCE and FIDELIO-DKD

Author

Agarwal, Rajiv, primary, Anker, Stefan D., additional, Filippatos, Gerasimos, additional, Pitt, Bertram, additional, Rossing, Peter, additional, Ruilope, Luis M., additional, Boletis, John, additional, Toto, Robert, additional, Umpierrez, Guillermo E., additional, Wanner, Christoph, additional, Wada, Takashi, additional, Scott, Charlie, additional, Joseph, Amer, additional, Ogbaa, Ike, additional, and Ro, Luke, additional

Published
2021
Full Text
View/download PDF

10. Phase III clinical trial end points in acute heart failure syndromes: A virtual roundtable with the acute heart failure syndromes international working group

Author

Gheorghiade, Mihai, Adams, Kirkwood F., Cleland, John G.F., Cotter, Gad, Felker, G. Michael, Filippatos, Gerasimos S., Fonarow, Gregg C., Greenberg, Barry H., Hernandez, Adrian F., Khan, Sadiya, Komajda, Michel, Konstam, Marvin A., Liu, Peter P., Maggioni, Aldo P., Massie, Barry M., McMurray, John J., Mehra, Mandeep, Metra, Marco, O'Connell, John, O'Connor, Christopher M., Pang, Peter S., Piña, Ileana L., Sabbah, Hani N., Teerlink, John R., Udelson, James E., Yancy, Clyde W., Zannad, Faiez, and Stockbridge, Norman

Published
2009
Full Text
View/download PDF

11. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: Results from the Hemodynamic, Ech ocardiographic, and Neu rohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomi zed C ontrolled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial

Author

Shah, Sanjiv J., Blair, John E.A., Filippatos, Gerasimos S., Macarie, Cezar, Ruzyllo, Witold, Korewicki, Jerzy, Bubenek-Turconi, Serban I., Ceracchi, Maurizio, Bianchetti, Maria, Carminati, Paolo, Kremastinos, Dimitrios, Grzybowski, Jacek, Valentini, Giovanni, Sabbah, Hani N., and Gheorghiade, Mihai

Published
2009
Full Text
View/download PDF

14. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: Results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial

Author

Shah, Sanjiv J., Blair, John E.A., Filippatos, Gerasimos S., Macarie, Cezar, Ruzyllo, Witold, Korewicki, Jerzy, Bubenek-Turconi, Serban I., Ceracchi, Maurizio, Bianchetti, Maria, Carminati, Paolo, Kremastinos, Dimitrios, Grzybowski, Jacek, Valentini, Giovanni, Sabbah, Hani N., and Gheorghiade, Mihai

Published
2009

15. Design of the RELAXin in Acute Heart Failure Study

Author

Ponikowski, Piotr, Metra, Marco, Teerlink, John R., Unemori, Elaine, Felker, Michael G., Voors, Adriaan A., Filippatos, Gerasimos, Greenberg, Barry, Teichman, Sam L., Severin, Thomas, Mueller-Velten, Guenther, Cotter, Gad, and Davison, Beth A.

Published
2012
Full Text
View/download PDF

17. Effects of serelaxin on the outcome of patients with or without substantial peripheral edema: A subgroup analysis from the RELAX-AHF trial

Author

Gimpelewicz, Claudio, primary, Metra, Marco, additional, Cleland, John G.F, additional, Szecsödy, Peter, additional, Chang Wun, Chuan-Chuan, additional, Boer-Martins, Leandro, additional, Cotter, Gad, additional, Davison, Beth A., additional, Felker, Gary Michael, additional, Filippatos, Gerasimos, additional, Greenberg, Barry H., additional, Pang, Peter, additional, Ponikowski, Piotr, additional, Severin, Thomas, additional, Voors, Adrian A., additional, and Teerlink, John R., additional

Published
2017
Full Text
View/download PDF

18. Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial

Author

Pang, Peter S., primary, Teerlink, John R., additional, Boer-Martins, Leandro, additional, Gimpelewicz, Claudio, additional, Davison, Beth A., additional, Wang, Yi, additional, Voors, Adriaan A., additional, Severin, Thomas, additional, Ponikowski, Piotr, additional, Hua, Tsushung A., additional, Greenberg, Barry H., additional, Filippatos, Gerasimos, additional, Felker, G. Michael, additional, Cotter, Gad, additional, and Metra, Marco, additional

Published
2017
Full Text
View/download PDF

19. Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.

Author

Parissis JT, Kourea K, Panou F, Farmakis D, Paraskevaidis I, Ikonomidis I, Filippatos G, and Kremastinos DT

Subjects
Aged, Anemia etiology, Cardiomyopathy, Dilated complications, Darbepoetin alfa, Drug Therapy, Combination, Echocardiography, Erythropoietin pharmacology, Erythropoietin therapeutic use, Exercise Tolerance, Heart Failure blood, Heart Failure drug therapy, Heart Failure etiology, Hematinics pharmacology, Hemodynamics, Humans, Injections, Subcutaneous, Single-Blind Method, Anemia drug therapy, Erythropoietin analogs & derivatives, Heart Failure physiopathology, Hematinics therapeutic use, Ventricular Function, Left drug effects, Ventricular Function, Right drug effects
Abstract

Background: Anemia is a frequent condition in chronic heart failure (CHF) that affects adversely long-term cardiac outcomes. We sought to investigate the effects of recombinant human erythropoietin analogue darbepoetin alpha on left (LV) and right ventricular (RV) function and neurohormonal activation in patients with CHF and anemia., Methods: Thirty-two CHF patients (New York Heart Association class II-III, LV ejection fraction [EF] <40%, hemoglobin level <12.5 g/dL, serum creatinine level <2.5 mg/dL) were randomized (2:1) to receive either a 3-month darbepoetin alpha regimen at 1.5 microg/kg every 20 days plus oral iron (n = 21) or placebo plus oral iron (n = 11). Echocardiographic indices of LV systolic and diastolic function and RV function, plasma B-type natriuretic peptide (BNP) and 6-minute walked distance were assessed at baseline and posttreatment., Results: Regarding LV function, only treatment with darbepoetin alpha caused a significant improvement in LVEF (F = 22.001, P < .001), end-systolic wall stress (F = 4.934, P = .034), mitral annulus systolic displacement (F = 6.710, P < .015), isovolumic relaxation time (F = 4.909, P = .035), and E/e ratio (F = 7.833, P = .009). The RV systolic pressure (F = 7.715, P = .009) as well as tricuspid annulus systolic displacement and RVEF (F = 9.264, P = .005) were significantly improved only in the darbepoetin alpha group. Darbepoetin alpha had also alpha beneficial effect on New York Heart Association class (F = 14.586, P = .001), plasma BNP (F = 14.781, P = .001), and 6-minute walk test (F = 19.926, P < .001), whereas these parameters did not significantly change in the placebo-treated patients., Conclusion: Darbepoetin alpha improves both LV and RV performance and exercise capacity and counteracts neurohormonal activation in CHF patients with anemia. The drug effects on LV diastolic function, RV function, and LV end-systolic wall stress, in particular, are novel findings, with a potential important contribution to patients' symptomatic improvement.

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results